CA2962239C - Uses of trehalose in cell suspensions - Google Patents
Uses of trehalose in cell suspensions Download PDFInfo
- Publication number
- CA2962239C CA2962239C CA2962239A CA2962239A CA2962239C CA 2962239 C CA2962239 C CA 2962239C CA 2962239 A CA2962239 A CA 2962239A CA 2962239 A CA2962239 A CA 2962239A CA 2962239 C CA2962239 C CA 2962239C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- trehalose
- cell suspension
- cell
- thawed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 title claims abstract description 111
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 title claims abstract description 110
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 title claims abstract description 110
- 239000006285 cell suspension Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 23
- 230000001413 cellular effect Effects 0.000 claims abstract description 13
- 238000010257 thawing Methods 0.000 claims abstract description 10
- 238000005138 cryopreservation Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 182
- 239000002609 medium Substances 0.000 claims description 28
- 239000012736 aqueous medium Substances 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 241000282465 Canis Species 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000005059 placental tissue Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000012895 dilution Substances 0.000 abstract description 4
- 238000010790 dilution Methods 0.000 abstract description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 8
- 229940050526 hydroxyethylstarch Drugs 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008121 dextrose Substances 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000012914 anti-clumping agent Substances 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010048654 Muscle fibrosis Diseases 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000007717 corneal ulcer Diseases 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940018607 vetstarch Drugs 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000018650 Intervertebral disc disease Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 208000003401 eosinophilic granuloma Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056842P | 2014-09-29 | 2014-09-29 | |
| US62/056,842 | 2014-09-29 | ||
| PCT/US2015/052950 WO2016069173A2 (en) | 2014-09-29 | 2015-09-29 | Uses of trehalose in cell suspensions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2962239A1 CA2962239A1 (en) | 2016-05-06 |
| CA2962239C true CA2962239C (en) | 2024-01-02 |
Family
ID=55583355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2962239A Active CA2962239C (en) | 2014-09-29 | 2015-09-29 | Uses of trehalose in cell suspensions |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160089401A1 (enExample) |
| EP (1) | EP3201319A4 (enExample) |
| JP (1) | JP2017531446A (enExample) |
| CN (1) | CN107106488A (enExample) |
| AU (1) | AU2015339886B2 (enExample) |
| BR (1) | BR112017006533A2 (enExample) |
| CA (1) | CA2962239C (enExample) |
| WO (1) | WO2016069173A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3525806B1 (en) * | 2016-10-12 | 2023-02-15 | Agency For Science, Technology And Research | Method for lyophilising an exosome |
| GB201716729D0 (en) * | 2017-10-12 | 2017-11-29 | Asymptote Ltd | Cryopreservation method and apparatus |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| AU2021267900A1 (en) | 2020-05-08 | 2023-01-19 | Gallant Pet Inc. | Uterine-derived regenerative cell compositions and uses thereof |
| CN111856022A (zh) * | 2020-07-01 | 2020-10-30 | 山东凯歌智能机器有限公司 | 一种检测胰腺癌患者外周血循环肿瘤细胞E-Cadherin表达的试剂盒及检测方法 |
| CN111638341A (zh) * | 2020-07-01 | 2020-09-08 | 山东凯歌智能机器有限公司 | 一种检测小细胞肺癌患者外周血循环肿瘤细胞pd-l1基因突变的试剂盒及检测方法 |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| CA3195653A1 (en) | 2020-10-14 | 2022-04-21 | Ossium Health, Inc. | Systems and methods for extraction and cryopreservation of bone marrow |
| WO2022133282A1 (en) | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
| US20240060049A1 (en) | 2020-12-19 | 2024-02-22 | Habil F KHORAKIWALA | Lyophilized mesenchymal stem cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2194911T3 (es) * | 1994-06-02 | 2003-12-01 | Elan Drug Delivery Ltd | Metodo para evitar la agregacion de proteinas/peptidos cuando tiene lugar su rehidratacion o descongelacion. |
| DE59804785D1 (de) * | 1997-11-22 | 2002-08-22 | Roche Diagnostics Gmbh | Verbessertes Verfahren zur Stabilisierung von Proteinen |
| US20060134596A1 (en) * | 2003-05-08 | 2006-06-22 | Anita Sjogren | Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method |
| EP1841856A1 (en) * | 2005-01-28 | 2007-10-10 | Canadian Blood Services | A method of cryopreserving cells and tissues by liposomal delivery of sugars to enhance post-thaw viability |
| CA2635978A1 (en) * | 2006-01-04 | 2007-07-12 | Do-Coop Technologies Ltd. | Solid-fluid composition |
| KR20240052847A (ko) * | 2008-08-20 | 2024-04-23 | 셀룰래리티 인코포레이티드 | 개선된 세포 조성물 및 그의 제조 방법 |
| JP5940975B2 (ja) * | 2009-07-20 | 2016-06-29 | ザ ジェネラル ホスピタル コーポレーション ディー／ビー／エイ マサチューセッツ ジェネラル ホスピタル | 凍結保存細胞の生存率を向上させるための方法および組成物 |
| CN103180435A (zh) * | 2010-08-31 | 2013-06-26 | 库克通用生物技术有限责任公司 | 用于治疗动物疾病的全身的同种异体干细胞疗法 |
| JP5341059B2 (ja) * | 2010-11-09 | 2013-11-13 | 株式会社大塚製薬工場 | 幹細胞懸濁液 |
| MX370199B (es) * | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
| JP5432322B2 (ja) * | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| JP5196618B1 (ja) * | 2012-09-28 | 2013-05-15 | 株式会社大塚製薬工場 | トレハロース含有細胞洗浄溶液を用いた接着細胞の洗浄方法 |
| CN104161037B (zh) * | 2014-08-13 | 2016-01-13 | 江苏丘陵地区镇江农业科学研究所 | 一种山羊精液玻璃化冷冻和解冻配方与方法 |
| CN105052894B (zh) * | 2015-08-26 | 2018-03-06 | 中国农业科学院特产研究所 | 一种gv期卵母细胞冷冻保存液及冷冻保存方法 |
-
2015
- 2015-09-29 CN CN201580062294.3A patent/CN107106488A/zh active Pending
- 2015-09-29 WO PCT/US2015/052950 patent/WO2016069173A2/en not_active Ceased
- 2015-09-29 JP JP2017536231A patent/JP2017531446A/ja active Pending
- 2015-09-29 CA CA2962239A patent/CA2962239C/en active Active
- 2015-09-29 BR BR112017006533A patent/BR112017006533A2/pt not_active Application Discontinuation
- 2015-09-29 US US14/869,006 patent/US20160089401A1/en not_active Abandoned
- 2015-09-29 AU AU2015339886A patent/AU2015339886B2/en active Active
- 2015-09-29 EP EP15854446.0A patent/EP3201319A4/en not_active Withdrawn
-
2021
- 2021-05-07 US US17/302,633 patent/US20210252155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017531446A (ja) | 2017-10-26 |
| US20160089401A1 (en) | 2016-03-31 |
| WO2016069173A3 (en) | 2016-07-28 |
| BR112017006533A2 (pt) | 2017-12-19 |
| CA2962239A1 (en) | 2016-05-06 |
| EP3201319A2 (en) | 2017-08-09 |
| US20210252155A1 (en) | 2021-08-19 |
| CN107106488A (zh) | 2017-08-29 |
| AU2015339886A1 (en) | 2017-04-13 |
| AU2015339886B2 (en) | 2019-05-09 |
| EP3201319A4 (en) | 2018-05-16 |
| WO2016069173A2 (en) | 2016-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2962239C (en) | Uses of trehalose in cell suspensions | |
| KR101868653B1 (ko) | 줄기 세포 현탁액 | |
| US8642255B2 (en) | Materials and methods for hypothermic collection of whole blood | |
| CN104873542A (zh) | 一种脐带间充质干细胞注射液及其制备方法和应用 | |
| US20200383317A1 (en) | Viable cell compositions, and methods related to same | |
| WO2014203268A2 (en) | Method for isolation, purification and industrial scale expansion of equine adipose tissue derived mensenchymal stem cells | |
| JP5753874B2 (ja) | 細胞生存率低下抑制剤 | |
| WO2013168402A1 (ja) | デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液 | |
| JP2022159210A (ja) | 凍結接着性幹細胞の製造方法 | |
| CA3022685C (en) | Methods of cryopreservation of viable cells, compositions of viable cells and uses thereof | |
| EP4281131A1 (en) | Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications | |
| WO2022210574A1 (ja) | 筋ジストロフィー治療剤 | |
| JP2023148207A (ja) | 細胞製剤用非凍結保存液 | |
| HK1152841B (en) | Materials and methods for hypothermic collection of whole blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |
|
| EEER | Examination request |
Effective date: 20200925 |